Human influenza A virus causes myocardial and cardiac-specific conduction system infections associated with early inflammation and premature death.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
22 02 2021
Historique:
received: 21 01 2020
revised: 27 03 2020
accepted: 22 04 2020
pubmed: 30 4 2020
medline: 5 1 2022
entrez: 30 4 2020
Statut: ppublish

Résumé

Human influenza A virus (hIAV) infection is associated with important cardiovascular complications, although cardiac infection pathophysiology is poorly understood. We aimed to study the ability of hIAV of different pathogenicity to infect the mouse heart, and establish the relationship between the infective capacity and the associated in vivo, cellular and molecular alterations. We evaluated lung and heart viral titres in mice infected with either one of several hIAV strains inoculated intranasally. 3D reconstructions of infected cardiac tissue were used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells, and cardiac vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection and study underlying molecular alterations associated with the in vivo electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and replicated in cardiomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also present in cardiac endothelial cells. Remarkably, lung viral titres did not statistically correlate with viral titres in the mouse heart. The highly pathogenic human recombinant virus PAmut showed faster replication, higher level of inflammatory cytokines in cardiac tissue and higher viral titres in cardiac HL-1 mouse cells and hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction alterations were especially pronounced in PAmut-infected mice, associated with high mortality rates, compared with PB2mut-infected animals. Consistently, connexin43 and NaV1.5 expression decreased acutely in hiPSC-CMs infected with PAmut virus. YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected hiPSC-CMs compared with PB2mut-infected cells, consistent with mitochondrial dysfunction. Human IAV infection did not increase myocardial fibrosis at 4-day post-infection, although PAmut-infected mice showed an early increase in mRNAs expression of lysyl oxidase. Human IAV can infect the heart and cardiac-specific conduction system, which may contribute to cardiac complications and premature death.

Identifiants

pubmed: 32346730
pii: 5826367
doi: 10.1093/cvr/cvaa117
pmc: PMC7898948
doi:

Substances chimiques

Connexins 0
Cytokines 0
Inflammation Mediators 0
enhanced green fluorescent protein 0
Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

876-889

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL122352
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129136
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL138064
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Infect Chemother. 2015 Dec;47(4):272-7
pubmed: 26788413
Cases J. 2008 Jul 18;1(1):46
pubmed: 18638393
J Virol. 2004 Apr;78(8):3880-8
pubmed: 15047804
Lancet Infect Dis. 2009 Oct;9(10):601-10
pubmed: 19778762
Medicine (Baltimore). 2016 Mar;95(10):e2869
pubmed: 26962782
Int J Mol Sci. 2018 Dec 07;19(12):
pubmed: 30544562
PLoS Pathog. 2017 Oct 12;13(10):e1006650
pubmed: 29023600
Influenza Res Treat. 2012;2012:351979
pubmed: 23304476
JAMA Cardiol. 2016 Jun 1;1(3):274-81
pubmed: 27438105
Circ Res. 2018 May 25;122(11):1501-1516
pubmed: 29514831
Eur Heart J. 2011 Feb;32(3):283
pubmed: 20861138
J Cell Biol. 2019 Feb 4;218(2):598-614
pubmed: 30598479
J Am Coll Cardiol. 2003 Aug 6;42(3):466-72
pubmed: 12906974
Heart. 2005 Dec;91(12):1601-2
pubmed: 16287745
Nature. 2009 Jun 18;459(7249):931-9
pubmed: 19525932
Virchows Arch. 2011 Mar;458(3):371-6
pubmed: 21234762
Inflamm Res. 2012 Jun;61(6):591-8
pubmed: 22373653
EMBO J. 1999 Jul 1;18(13):3767-75
pubmed: 10393191
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
J Virol. 2017 Aug 24;91(18):
pubmed: 28679763
Mod Pathol. 2002 Sep;15(9):914-22
pubmed: 12218208
Cardiovasc Res. 2018 Jun 1;114(7):979-991
pubmed: 29490017
Lancet Infect Dis. 2010 Feb;10(2):83-92
pubmed: 20113977
Cardiovasc Res. 2011 Feb 15;89(3):595-603
pubmed: 21084314
Tohoku J Exp Med. 2001 Sep;195(1):11-9
pubmed: 11780720
Eur Heart J. 2007 May;28(10):1205-10
pubmed: 17440221
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18607-18612
pubmed: 31451661
J Clin Microbiol. 2010 Jun;48(6):2298-300
pubmed: 20392922
BMJ Case Rep. 2010 Sep 17;2010:
pubmed: 22778249
CMAJ. 2013 Apr 16;185(7):581-4
pubmed: 23549966
PLoS One. 2013;8(1):e53515
pubmed: 23326447
J Cell Sci. 2016 Aug 15;129(16):3084-90
pubmed: 27358477
J Infect Dis. 2012 Dec 1;206(11):1652-9
pubmed: 23048170
Cell Cycle. 2007 Aug 15;6(16):2043-7
pubmed: 17700063
J Formos Med Assoc. 2006 Jan;105(1):1-6
pubmed: 16440064
Cardiovasc Res. 2004 Jul 1;63(1):77-86
pubmed: 15194464
J Crit Care. 2012 Feb;27(1):106.e1-6
pubmed: 21737242
J Am Coll Cardiol. 2006 Oct 3;48(7):1498-502
pubmed: 17010820
Int J Cardiol. 2008 Nov 28;130(3):304-9
pubmed: 18625525
Cell Death Dis. 2013 Oct 31;4:e896
pubmed: 24176854
FEBS Lett. 2003 Sep 18;552(1):28-34
pubmed: 12972148
Proc Natl Acad Sci U S A. 1980 Apr;77(4):1857-61
pubmed: 6246509
Annu Rev Pathol. 2008;3:127-55
pubmed: 18039131
PLoS Pathog. 2009 May;5(5):e1000462
pubmed: 19478885
J Virol. 2007 May;81(10):5315-24
pubmed: 17344288
Heart. 2016 Dec 15;102(24):1953-1956
pubmed: 27686519

Auteurs

David Filgueiras-Rama (D)

Cardiac Electrophysiology Unit, Hospital Clínico San Carlos, Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Consortium CIBER of Cardiovascular Diseases (CIBERCV), Spain.

Jasmina Vasilijevic (J)

Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain.
Consortium CIBER of Respiratory Diseases, Spain.

Jose Jalife (J)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Consortium CIBER of Cardiovascular Diseases (CIBERCV), Spain.
Center for Arrhythmia Research, Health System, University of Michigan, MI, USA.

Sami F Noujaim (SF)

Morsani College of Medicine Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL, USA.

Jose M Alfonso (JM)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Jose A Nicolas-Avila (JA)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Celia Gutierrez (C)

Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain.

Noelia Zamarreño (N)

Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain.

Andres Hidalgo (A)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Alejandro Bernabé (A)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Christopher Pablo Cop (CP)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Daniela Ponce-Balbuena (D)

Center for Arrhythmia Research, Health System, University of Michigan, MI, USA.

Guadalupe Guerrero-Serna (G)

Center for Arrhythmia Research, Health System, University of Michigan, MI, USA.

Daniel Calle (D)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Manuel Desco (M)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Department of Bioengineering and Aerospace Engineering, University Carlos III of Madrid, Madrid, Spain.
Consortium CIBER of Mental Health (CIBERSAM), Spain.

Jesus Ruiz-Cabello (J)

Consortium CIBER of Respiratory Diseases, Spain.
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), San Sebastian, Spain.
IKERBASQUE, Basque Foundation for Science, Spain.
Universidad Complutense Madrid, Madrid, Spain.

Amelia Nieto (A)

Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain.
Consortium CIBER of Respiratory Diseases, Spain.

Ana Falcon (A)

Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council, Madrid, Spain.
Consortium CIBER of Respiratory Diseases, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH